Search Results
Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC
Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC
Dr. Shaw Discusses Efficacy of Lorlatinib in ALK+ NSCLC
Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer
CROWN: biomarkers for lorlatinib response in patients with ALK+ NSCLC
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI
Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
Dr. Oxnard Discusses RET Fusions in NSCLC
Clinical updates on ALK inhibitor treatment strategies for NSCLC
Dr. Geoff Oxnard Discusses the Role of Precision Medicine in Lung Cancer Research
Lorlatinib for chemotherapy-refractory and alectinib-refractory patients with ALK+ LBCL
How Do We Make EGFR Inhibitors Work Better for Patients
